A San Francisco-based biotech company, backed by OpenAI’s Sam Altman, has won government approval to begin clinical trials of a new “safer MDMA”.
The company, Arcadia Medicine, which is developing psychoactive drugs to treat mental health disorders, could deliver early-stage clinical trial results within a year.